Expand Document | Expand Chapter | Full TOC | Printable HTML version
First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Sources of information and study methodology
Open this folder and view contents3. Dissemination and uptake of the Guidelines
Open this folder and view contents4. Basic characteristics of drug donations
Open this folder and view contents5. Practical benefits as a result of the Guidelines
View the document6. Drug donations which were hampered, delayed or cancelled
Open this folder and view contents7. Experiences and opinions regarding the 12-month shelf-life requirement
Open this folder and view contents8. Other suggestions to improve the Guidelines
Open this folder and view contents9. How could donation practice be further improved?
View the document10. Summary of recommendations
View the document11. Postscript
View the documentReferences
 

References

1. Autier P et al. Drug supply in the aftermath of the 1988 Armenian earthquake. Lancet 1990; i:1388–1390.

2. Forte GB et al. An ounce of prevention is worth a pound of cure. Presentation at the International Conference of Drug Regulatory Agencies, The Hague, 1994.

3. MSH/WHO/DAP. Managing drug supply. 2nd edition. Hartford, CT: Kumarian Press, 1997. Management Sciences for Health in collaboration with World Health Organization, Action Programme on Essential Drugs. Edited by Quick JD, Rankin J, Laing RO, O’Connor R, Hogerzeil HV, Dukes MNG, and Garnet A.

4. Reich MR, editor. An assessment of US pharmaceutical donations: players, processes and products. Boston: Harvard School of Public Health, 1999.

to previous section
 

Last updated: May 3, 2013